[{"id":"6c440b25-6764-4263-b4a4-84f133298de5","acronym":"","url":"https://clinicaltrials.gov/study/NCT06091930","created_at":"2023-10-23T20:13:35.686Z","updated_at":"2024-07-02T16:35:06.730Z","phase":"Phase 1","brief_title":"A Study to Test Different Doses of BI 765049 Alone and in Combination With Ezabenlimab in Asian People With Advanced Cancer (Solid Tumours) Positive for B7-H6","source_id_and_acronym":"NCT06091930","lead_sponsor":"Boehringer Ingelheim","biomarkers":" NCR3LG1","pipe":"","alterations":" ","tags":["NCR3LG1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ezabenlimab (BI 754091) • BI 765049"],"overall_status":"Recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 01/31/2024","start_date":" 01/31/2024","primary_txt":" Primary completion: 11/13/2026","primary_completion_date":" 11/13/2026","study_txt":" Completion: 02/11/2027","study_completion_date":" 02/11/2027","last_update_posted":"2024-05-01"},{"id":"5afb8f35-987a-4b31-ac0f-ac4ece437bab","acronym":"","url":"https://clinicaltrials.gov/study/NCT04752215","created_at":"2022-05-26T22:56:02.452Z","updated_at":"2024-07-02T16:35:13.942Z","phase":"Phase 1","brief_title":"A Study Evaluating Different Doses of BI 765049 When Given Alone and When Given With Ezabenlimab to Patients With Advanced Solid Tumors Expressing the Protein B7-H6 on the Cell Surface","source_id_and_acronym":"NCT04752215","lead_sponsor":"Boehringer Ingelheim","biomarkers":" NCR3LG1","pipe":"","alterations":" ","tags":["NCR3LG1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ezabenlimab (BI 754091) • BI 765049"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 05/06/2021","start_date":" 05/06/2021","primary_txt":" Primary completion: 12/23/2025","primary_completion_date":" 12/23/2025","study_txt":" Completion: 12/31/2028","study_completion_date":" 12/31/2028","last_update_posted":"2024-03-19"}]